Antibody Drug Conjugates in Non-Small Cell Lung Cancer: Where is the Target and the Biomarker?

Abstract ADCs are an emerging treatment of NSCLC. Some do not require biomarkers, while others require mutations and/or protein expression. New diagnostic technologies give opportunities for better target identification and selection of patients. Combination therapies might broaden relevant patient populations but might call for combined biomarker selection paradigms.